首页 | 本学科首页   官方微博 | 高级检索  
检索        

��������2008~2014��좼����Ʋ�����Ӧ����
引用本文:����,��һ,��ˮ,�Ų�,÷��,���.��������2008~2014��좼����Ʋ�����Ӧ����[J].中国药学杂志,2015,50(18):1634-1638.
作者姓名:����  ��һ  ��ˮ  �Ų�  ÷��  ���
作者单位:1.?й???????????Э?????????Э????,???? 100730;
2.?????????????,???? 100044;
3. ú?????,???? 100028;
4.??????????????????????,???? 100024
摘    要:

关 键 词:??????  ?????????  ????  

Analysis of Foscarnet-induced Adverse Drug Reaction in Beijing Area from 2008 to 2014
HU Yang,LIU Yi,LIU Shui,WANG Lan,ZHANG Bo,MEI Dan,ZHU Lan.Analysis of Foscarnet-induced Adverse Drug Reaction in Beijing Area from 2008 to 2014[J].Chinese Pharmaceutical Journal,2015,50(18):1634-1638.
Authors:HU Yang  LIU Yi  LIU Shui  WANG Lan  ZHANG Bo  MEI Dan  ZHU Lan
Institution:1. Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China;
2. Peking University People??s Hospital, Beijing 100044, China 3. MeiTan Hospital,Beijing 100028, China;
4. Beijing Center for ADR Monitoring,Beijing 100024,China
Abstract:??OBJECTIVE To analyze the reports of foscarnet-induced adverse drug reaction (ADR) in Beijing area in the recent 6 years, and to provide reference for rational use of foscarnet.METHODS One hundred and fifty-two reports of ADR from March 2008 to December 2014 induced by foscarnet received by Beijing drug adverse reaction monitoring center were collected. The type and time of ADR,the age of patient, the gender and nation of patient, serious adverse reactions, allergy history, administration, dosage, preparation, the indication,ADR history,ADR involved organ and system ,the causal relationship, treatments and prognosis were retrospectively analyzed.RESULTS The ADR induced by foscarnet were more often occurred in patients aged from 31 to 60, with 55.3% appearing within 24 h after drug use. The clinical presentation was complex and diverse, which involved different systems and organs, predominantly the lesion of renal function and epilepticseizures.CONCLUSION Safe to use with foscarnet is worth paying attention by clinicans, who should detect and deal with ADR of foscarnet in time on basis of rational use.
Keywords:
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号